Morningstar

Illumina Inc ILMN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$139.02 +10.04 (7.78%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Illumina Highlights Weaker Growth Prospects at Investor Day Than Previously Expected

Julie Utterback

Illumina aims to transform human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to help researchers and clinicians identify and understand genetic variations. The scale of these projects can be wide, such as population genomic initiatives being pursued in many countries, or narrow, such as noninvasive prenatal screening. We believe Illumina will continue to benefit from the rapidly expanding applications of genomic sequencing tools through its own innovation and select acquisitions.

Read Full Report

Price vs Fair Value

View History
ILMN is trading within a range we consider fairly valued.
Price
$139.02
Fair Value
$154.00
Uncertainty
High
1-Star Price
$186.80
5-Star Price
$77.20
Economic Moat
Vcqdtz
Capital Allocation
Gjbkgtryg

Bulls Say, Bears Say

Bulls

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth opportunities for Illumina with or without Grail.

Bears

Disruptive technology risks could threaten Illumina's industry-leading sequencing platform, leading to market share losses and profit declines.

Show More

News

View All

Trading Information

Previous Close Price
$128.98
Day Range
$127.01–139.40
52-Week Range
$86.50–143.56
Bid/Ask
$139.32 / $139.70
Market Cap
$22.15 Bil
Volume/Avg
2.6 Mil / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
151.11
Price/Sales
4.98
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
9,300
Website
https://www.illumina.com

Competitors

Valuation

View More
Metric
ILMN
EXAS
TMO
Price/Earnings (Normalized)
 151.11707.9628.05
Price/Book Value
 15.423.874.93
Price/Sales
 4.984.665.58
Price/Cash Flow
 57.2362.3027.48
Price/Earnings
ILMN
EXAS
TMO

Financial Strength

Metric
ILMN
EXAS
TMO
Quick Ratio
 0.741.811.24
Current Ratio
 1.112.171.72
Interest Coverage
 −39.58−7.234.91
Quick Ratio
ILMN
EXAS
TMO

Profitability

Metric
ILMN
EXAS
TMO
Return on Assets (Normalized)
 1.51%0.13%8.68%
Return on Equity (Normalized)
 2.86%0.26%18.42%
Return on Invested Capital (Normalized)
 2.18%0.43%10.79%
Return on Assets
ILMN
EXAS
TMO

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
DypvrhgdlCjft$234.1 Bil
 Danaher Corp
DHR
NjlvhlvvqTphcfv$197.8 Bil
 IQVIA Holdings Inc
IQV
DjmqjshzCnbnwl$42.2 Bil
 Agilent Technologies Inc
A
MzmyffknkTjm$42.1 Bil
 IDEXX Laboratories Inc
IDXX
XmxmdvdkmqVvbck$40.0 Bil
 Mettler-Toledo International Inc
MTD
NpwzkvcwcqMdlmsq$31.8 Bil
 Icon PLC
ICLR
FhfqflspHjqsmz$24.4 Bil
 Waters Corp
WAT
ChzwvzswssGzd$21.1 Bil
 Labcorp Holdings Inc
LH
WztbrkhypxMdqbvfg$18.4 Bil

Sponsor Center